On Thursday, Novavax Inc (NVAX) stock saw a decline, ending the day at $9.92 which represents a decrease of $-0.08 or -0.80% from the prior close of $10. The stock opened at $10 and touched a low of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

临床暂停的原因是，CIC 2期试验中，一名于2023年1月接受该疫苗的 非美国受试者自发报告了严重不良事件 （SAE）——运动神经病变。该试验于2023年7月完成，受试者于2024年9月报告SAE。

A look at some of the Health Report correspondence this week.   You can email us at healthreport@abc.net.au ...

Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk ...

Novavax Inc.’s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its ...

在一名临床试验参与者发生严重不良事件後，Novavax(NVAX.US)遭美国食品和药物管理局暂停其实验性流感疫苗的开发，该股股价周三下挫20%。

投资慧眼Insights - 辉瑞对手、美国疫苗制造商诺瓦瓦克斯Novavax年中因与制药巨头赛诺菲的合作而逆转疫情后颓势，创下两日股价暴涨200%的「重生」传奇。而该公司近日因实验安全问题被美国FDA暂停临床试验，股价闪崩近20%。 周三（10月16日），诺瓦瓦克斯表示，在一名美国境外的试验参与者发生了严重运动神经病变后，美国食品药品监督管理局FDA暂停了这家公司的「流感/新冠联合疫苗」临床试验 ...

Novavax's shares are tumbling after the company disclosed that regulators paused clinical trials for two key vaccine ...

Novavax’s plans for growth outside of its COVID program have been thrown into chaos after the FDA put the biooharma's flu ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has placed a ...

Novavax shares tumbled after the Food and Drug Administration put a clinical hold on its testing applications for a combined ...